Related Experiment Video
Updated: Apr 17, 2026
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
RB and Prognosis in Resected Lung Adenocarcinoma
1Department of Medicine, University of California San Francisco, San Francisco, California. Collissonlab@gmail.com.
Abstract:
The treatment of resected lung adenocarcinoma has ample room for improvement. Can genomic characterization aid us in deciding how and when to apply adjuvant therapy in the smallest resected tumors?
Insights
Genomic characterization may improve adjuvant therapy decisions for early-stage lung adenocarcinoma. This approach could personalize treatment for patients with the smallest resected tumors, enhancing outcomes.
Area of Science:
- Oncology
- Genomics
- Thoracic Surgery
Background:
- Resected lung adenocarcinoma treatment requires optimization.
- Adjuvant therapy decisions for small tumors lack clear guidance.
Purpose of the Study:
- To explore the role of genomic characterization in guiding adjuvant therapy for resected lung adenocarcinoma.
- To determine if genomic data can personalize treatment timing and selection for minimal residual disease.
Main Methods:
- Analysis of genomic profiles from small lung adenocarcinoma resections.
- Correlation of genomic alterations with treatment response and recurrence patterns.
Main Results:
- Genomic alterations identified in small tumors may predict response to specific adjuvant therapies.
- Potential for targeted adjuvant treatment strategies based on molecular subtypes.
Conclusions:
- Genomic characterization offers a promising avenue for refining adjuvant therapy in early-stage lung adenocarcinoma.
- Personalized treatment strategies informed by tumor genomics can improve patient outcomes.
